Clinical trials: Type 2 Diabetes Mellitus 1
Type 1 Diabetes Mellitus
Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion
Primary Objective: Assess the safety of SAR342434 and Humalog when used in external pumps. Secondary Objectives: Intervals for infusion set changes. Incidence of insulin pump alarms for infusion set occlusion.
- Trial name
- NCT02603510
- Testing
- SAR342434, insulin lispro
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Sanofi
Pancreatic Cancer
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
EXCEED is a non-interventional post-authorisation safety study aiming to assess the risk of developing pancreatic cancer among type 2 diabetes mellitus (T2DM) patients who initiated exenatide compared to those who initiated other…
- Trial name
- EXCEED (NCT05663515)
- Testing
- Exenatide, Non-GLP-1 RA based glucose lowering drugs
- Where
- 8 sites in Denmark, Finland and 5 more
- Volunteers
- 24,000 people
- Sponsor
- AstraZeneca
Type 1 Diabetes, Type 1 Diabetes Mellitus Maturity Onset
Evaluating ImmuNe Changes in the Evolution of Pre Type 1 Diabetes With Adult ONset
Little is known about how type 1 diabetes or coeliac disease develop in adults. Studies following children at risk of type 1 diabetes from birth have shown that the marker of type 1 diabetes autoimmunity (antibodies against the…
- Trial name
- INCEPTiON (NCT06006468)
- Testing
- High genetic risk for type 1 diabetes, High gentic risk for Coeliac disease
- Where
- United Kingdom
- Volunteers
- 2,250 people, healthy volunteers welcome
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Diabetes Mellitus
Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus
Primary Objectives: To determine the effect of insulin glulisine on glycemic control (HbA1c, FBG \& PPBG) from baseline to the end of the study.
- Trial name
- SCALE (NCT00526513)
- Testing
- Insulin Glulisine
- Where
- Egypt
- Volunteers
- 188 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Retinal Function in Diabetic Patients Without Retinopathy
The primary purpose was to assess, in diabetic patients without diabetic retinopathy and control subjects, color vision, contrast sensitivity, electroretinography, and flicker-induced vasodilatation using the Dynamic Vessel…
- Trial name
- NEURODIAB (NCT00839150)
- Where
- France
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
A 13-week multi-center single-arm trial, preceded by a 2-week standard therapy phase, will be conducted to assess the safety of MODI, an insulin titration algorithm, in adults with type 1 diabetes (T1D) who use multiple daily…
- Trial name
- MODIUS (NCT07599982)
- Testing
- MODI Algorithm
- Where
- 6 sites in United States
- Volunteers
- 102 people
- Sponsor
- DreaMed Diabetes
Type 2 Diabetes
Lifestyle Intervention in Obesity, Effect on Diabetes
There are evidence from numerous studies on effect of lifestyle intervention in morbidly obese patients with type 2 diabetes. This study examines the effect of the "Evje-model" on type 2 diabetes.
- Trial name
- NCT00466362
- Testing
- The Evje Model
- Where
- Norway
- Sponsor
- Tor-Ivar Karlsen
Type 1 Diabetes Mellitus
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
To obtain safety and tolerability information in patients with type 1 diabetes where Dapagliflozin is added on to Insulin (for 14 days)
- Trial name
- NCT01498185
- Testing
- Dapagliflozin
- Where
- 12 sites in United States
- Volunteers
- 171 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Non-Insulin-Dependent
NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes
The purpose of this research study is to investigate the mechanism of action of a new investigational medication (drug), NNC 90-1170, which is being developed for the treatment of type 2 diabetes (adult onset type of diabetes.
- Trial name
- NCT00013910
- Testing
- NNC 90-1170
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
Diabetes Mellitus Type I, Diabetes Mellitus Type II
Collection of Performance Data From the Integrated Sensor and Infusion Set. TRIAL 4
This is a multi-center, non-randomized, and interventional study in which subjects will use the Integrated sensor and infusion set with MiniLink Transmitter and the Medtronic Paradigm® VEO™ insulin pump (Sensor augmented pump)…
- Trial name
- NCT01775059
- Testing
- Integrated sensor and infusion set.
- Where
- 3 sites in Denmark
- Volunteers
- 50 people
- Sponsor
- Medtronic Diabetes R&D Denmark
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
This study is an open label, prospective, randomised comparative, single center study. In the present study, the impact of a 12-week pulsatile insulin infusion therapy (PIT) with Humulin R 100 from
- Trial name
- NCT04030091
- Testing
- 3 hours humulin R 100 IU/mL PIT, 2 hours humulin R 100 IU/mL PIT
- Where
- 2 sites in United States, Germany
- Volunteers
- 24 people
- Sponsor
- Sciema UG
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in Asia, Europe and Oceania. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart) with biphasic insulin aspart 30 in subjects with type 2 diabetes.
- Trial name
- BOOST™ (NCT01009580)
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart 30
- Where
- 53 sites in Australia, Denmark and 8 more
- Volunteers
- 447 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.
To explore the mechanism of action of ranolazine as a potential treatment for type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01843127
- Testing
- Ranolazine, Exenatide
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Gilead Sciences
Type 2 Diabetes Mellitus
A Study To Estimate The Effect Of Repeated Dosing of PF-05175157 On The Pharmacokinetics Of A Single Dose Of Simvastatin In Healthy Adult Subjects
The study is designed to investigate the effect of repeated dosing of PF-05175157 on the pharmacokinetics of a single dose of Simvastatin in healthy adult subjects.
- Trial name
- NCT01469468
- Testing
- Simvastatin, PF-05175157
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus
The Daytime Circadian Rhythm in Exhaled Volatile Organic Compounds in People Living Without and Diabetes
Exhaled volatile organic compounds will be measured during daytime with the goal to identifying circadian variability. The study incudes three subgroups: people without diabetes, people with type 1 diabetes, and people with type…
- Trial name
- VOCircle (NCT05984979)
- Testing
- Standardized meal
- Where
- Switzerland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Bern
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes
This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the absorption and effect in the body of NN1218 in subjects with type 1 and type 2 diabetes.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01121276
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Type 2 Diabetes
Feasibility Study - Integrated Sensor and Infusion Set. Trial III
The purpose of this study is to collect performance data on the Integrated sensor and infusion set during 3 days of use and demonstrate performance adequacy of the integrated sensor and infusion set with glucose sensing and…
- Trial name
- NCT01773668
- Testing
- Integrated sensor and infusion set.
- Where
- Sweden
- Volunteers
- 17 people
- Sponsor
- Medtronic Diabetes R&D Denmark
Type 1 Diabetes
Glycemic Outcomes and Safety With Minimed 780G System in Children With Type 1 Diabetes Aged 2-6 Years
The purpose of this study is to evaluate the effectiveness of advanced hybrid-closed loop system, Minimed 780G to glycemic control and safety in children aged 2-6 years with type 1 diabetes.
- Trial name
- NCT04949022
- Testing
- Medronic 780G insulin pump
- Where
- Finland
- Volunteers
- 38 people
- Sponsor
- Helsinki University Central Hospital
Diabetic Macular Edema, Type 1 Diabetes Mellitus
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
The primary objective of the study is to determine if treatment with high-dose aflibercept (HD) at intervals of 12 or 16 weeks provides non-inferior best corrected visual acuity (BCVA) compared to aflibercept dosed every 8 weeks.
- Conditions
- Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Trial name
- PHOTON (NCT04429503)
- Testing
- aflibercept, High-dose aflibercept
- Where
- 138 sites in United States, Canada and 6 more
- Volunteers
- 660 people
- Sponsor
- Regeneron Pharmaceuticals
Xerosis Cutis, Diabetes Mellitus, Type 2
Effect of Centella Asiatica on Xerotic Skin in Diabetes Mellitus Type 2
The objective of this study is to evaluate the effect of Centella asiatica on hydration status of lower leg skin of DM type 2 patients by measuring SRRC and Skin Capacitance in correlation with AGEs CML, inflammation marker…
- Trial name
- NCT03815305
- Testing
- Centella Asiatica Extract, Topical CA, Petroleum jelly
- Where
- Indonesia
- Volunteers
- 159 people
- Sponsor
- Universitas Indonesia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.